MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone972-8932-4010
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.40 million
Profitability
Miscellaneous
Employees73
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Mediwound (NASDAQ:MDWD) Frequently Asked Questions
What is Mediwound's stock symbol?
Mediwound trades on the NASDAQ under the ticker symbol "MDWD."
How were Mediwound's earnings last quarter?
Mediwound Ltd (NASDAQ:MDWD) posted its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. The biopharmaceutical company had revenue of $20.75 million for the quarter, compared to analyst estimates of $7.03 million. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%. View Mediwound's Earnings History.
When is Mediwound's next earnings date?
What price target have analysts set for MDWD?
3 brokerages have issued 1-year target prices for Mediwound's stock. Their forecasts range from $5.50 to $11.00. On average, they expect Mediwound's stock price to reach $7.8333 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price. View Analyst Price Targets for Mediwound.
What is the consensus analysts' recommendation for Mediwound?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.
What are Wall Street analysts saying about Mediwound stock?
Here are some recent quotes from research analysts about Mediwound stock:
- 1. HC Wainwright analysts commented, "We are initiating coverage of MDWD with 12- month price target of $5.50 per share. We derive our price target based on an NPV analysis of projected future revenues from 2030, assuming a 11% discount rate and a 0.5% terminal growth rate." (8/5/2019)
- 2. According to Zacks Investment Research, "MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. " (7/12/2019)
Has Mediwound been receiving favorable news coverage?
Headlines about MDWD stock have trended positive this week, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mediwound earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Mediwound.
Are investors shorting Mediwound?
Mediwound saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 191,100 shares, an increase of 10.3% from the June 30th total of 173,300 shares. Based on an average daily trading volume, of 72,600 shares, the short-interest ratio is currently 2.6 days. Currently, 1.2% of the shares of the stock are sold short. View Mediwound's Current Options Chain.
Who are some of Mediwound's key competitors?
Some companies that are related to Mediwound include Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ).
What other stocks do shareholders of Mediwound own?
Who are Mediwound's key executives?
Mediwound's management team includes the folowing people:
- Mr. Gal Cohen, Pres & CEO (Age 46)
- Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
- Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
- Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
- Dr. Ety Klinger, Chief R&D Officer (Age 57)
Who are Mediwound's major shareholders?
Mediwound's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.05%), ARK Investment Management LLC (0.35%), Oppenheimer & Co. Inc. (0.16%), JPMorgan Chase & Co. (0.13%), Menta Capital LLC (0.13%) and Sargent Investment Group LLC (0.11%).
Which major investors are selling Mediwound stock?
MDWD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Renaissance Technologies LLC and Menta Capital LLC.
Which major investors are buying Mediwound stock?
MDWD stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Sargent Investment Group LLC and Oppenheimer & Co. Inc..
How do I buy shares of Mediwound?
Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mediwound's stock price today?
One share of MDWD stock can currently be purchased for approximately $3.14.
How big of a company is Mediwound?
Mediwound has a market capitalization of $85.35 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.
What is Mediwound's official website?
How can I contact Mediwound?
Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]
MarketBeat Community Rating for Mediwound (NASDAQ MDWD)
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
